Holders — by stockHoldings — by fund
Rhenman & Partners Asset Management AB
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-09-30 · filed with the SEC up to 45 days after quarter end · CIK 0001599882
$902.9M
disclosed book value
93
positions
4.1%
largest position share
Positions, as of 2026-09-30
top 93 of 93 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | IOVAIOVANCE BIOTHERAPEUTICS INC | 2.5M | $37.1M | 4.1% |
| 2 | AZNASTRAZENECA PLC | 185,000 | $30.3M | 3.4% |
| 3 | MRKMERCK & CO. INC | 206,900 | $30.1M | 3.3% |
| 4 | MDTMEDTRONIC PLC | 340,000 | $29.3M | 3.2% |
| 5 | UNHUNITEDHEALTH GROUP INC | 71,400 | $26.2M | 2.9% |
| 6 | VRTXVERTEX PHARMACEUTICALS INC | 48,935 | $25.6M | 2.8% |
| 7 | GILDGILEAD SCIENCES INC | 159,050 | $23.7M | 2.6% |
| 8 | EWEDWARDS LIFESCIENCES CORP | 273,000 | $23.6M | 2.6% |
| 9 | BMRNBIOMARIN PHARMACEUTICAL INC | 386,900 | $23.2M | 2.6% |
| 10 | BIIBBIOGEN INC | 97,050 | $21.9M | 2.4% |
| 11 | LLYELI LILLY & CO | 18,875 | $21.8M | 2.4% |
| 12 | INSMINSMED INC | 187,080 | $21.4M | 2.4% |
| 13 | CVSCVS HEALTH CORP | 220,374 | $18.9M | 2.1% |
| 14 | CORCENCORA INC | 62,478 | $18.8M | 2.1% |
| 15 | AXSMAXSOME THERAPEUTICS INC. | 97,735 | $18.0M | 2% |
| 16 | ABBVABBVIE INC | 61,625 | $16.1M | 1.8% |
| 17 | JAZZJAZZ PHARMACEUTICALS PLC | 67,825 | $15.7M | 1.7% |
| 18 | JNJJOHNSON & JOHNSON | 58,500 | $15.5M | 1.7% |
| 19 | MCKMCKESSON CORP | 17,850 | $15.2M | 1.7% |
| 20 | DHRDANAHER CORP DEL | 68,461 | $15.2M | 1.7% |
| 21 | CNCCENTENE CORP DEL | 237,481 | $14.8M | 1.6% |
| 22 | REGNREGENERON PHARMACEUTICALS | 19,340 | $14.7M | 1.6% |
| 23 | CRLCHARLES RIV LABS INTL INC | 46,800 | $13.8M | 1.5% |
| 24 | BSXBOSTON SCIENTIFIC CORP | 315,000 | $13.7M | 1.5% |
| 25 | ISRGINTUITIVE SURGICAL INC | 33,500 | $13.6M | 1.5% |
| 26 | GHGUARDANT HEALTH INC | 76,250 | $13.6M | 1.5% |
| 27 | THCTENET HEALTHCARE CORP | 52,787 | $13.5M | 1.5% |
| 28 | AAGILENT TECHNOLOGIES INC | 78,000 | $13.4M | 1.5% |
| 29 | ALKSALKERMES PLC | 302,640 | $12.3M | 1.4% |
| 30 | AVRANTERIS TECHNOLOGIES GLOBAL | 1.5M | $12.0M | 1.3% |
| 31 | NBIXNEUROCRINE BIOSCIENCES INC | 81,291 | $11.5M | 1.3% |
| 32 | ALHCALIGNMENT HEALTHCARE INC | 1.4M | $11.3M | 1.2% |
| 33 | BTSGBRIGHTSPRING HEALTH SVCS INC | 192,896 | $10.9M | 1.2% |
| 34 | LIVNLIVANOVA PLC | 140,004 | $10.7M | 1.2% |
| 35 | TMOTHERMO FISHER SCIENTIFIC INC | 15,563 | $10.5M | 1.2% |
| 36 | NRIXNURIX THERAPEUTICS INC | 439,500 | $10.4M | 1.2% |
| 37 | UTHRUNITED THERAPEUTICS CORP DEL | 19,150 | $10.4M | 1.1% |
| 38 | COOCOOPER COS INC | 181,500 | $10.3M | 1.1% |
| 39 | PRCTPROCEPT BIOROBOTICS CORP | 535,000 | $9.7M | 1.1% |
| 40 | PNTGPENNANT GROUP INC | 236,499 | $9.2M | 1% |
| 41 | ERASERASCA INC | 608,750 | $8.9M | 1% |
| 42 | RPRXROYALTY PHARMA PLC | 141,000 | $8.2M | 0.9% |
| 43 | EHCENCOMPASS HEALTH CORP | 66,263 | $8.1M | 0.9% |
| 44 | MIRMMIRUM PHARMACEUTICALS INC | 91,855 | $7.9M | 0.9% |
| 45 | VERAVERA THERAPEUTICS INC | 242,500 | $7.8M | 0.9% |
| 46 | ARWRARROWHEAD PHARMACEUTICALS IN | 112,500 | $7.4M | 0.8% |
| 47 | SYRESPYRE THERAPEUTICS INC | 78,600 | $7.0M | 0.8% |
| 48 | OSCROSCAR HEALTH INC | 220,000 | $6.8M | 0.8% |
| 49 | CYTKCYTOKINETICS INC | 102,800 | $6.8M | 0.8% |
| 50 | STVNSTEVANATO GROUP S P A | 316,838 | $6.6M | 0.7% |
| 51 | DNTHDIANTHUS THERAPEUTICS INC | 75,027 | $6.6M | 0.7% |
| 52 | HUMHUMANA INC | 17,000 | $6.5M | 0.7% |
| 53 | SNDXSYNDAX PHARMACEUTICALS INC | 342,250 | $6.4M | 0.7% |
| 54 | ALNYALNYLAM PHARMACEUTICALS INC | 25,900 | $6.4M | 0.7% |
| 55 | DXCMDEXCOM INC | 73,000 | $6.3M | 0.7% |
| 56 | RLAYRELAY THERAPEUTICS INC | 343,500 | $6.2M | 0.7% |
| 57 | NKTRNEKTAR THERAPEUTICS | 98,380 | $6.0M | 0.7% |
| 58 | GPCRSTRUCTURE THERAPEUTICS INC | 183,300 | $5.7M | 0.6% |
| 59 | IDYAIDEAYA BIOSCIENCES INC | 140,185 | $5.4M | 0.6% |
| 60 | KURAKURA ONCOLOGY INC | 501,050 | $5.4M | 0.6% |
| 61 | TGTXTG THERAPEUTICS INC | 90,500 | $5.0M | 0.6% |
| 62 | ABTABBOTT LABORATORIES | 49,500 | $4.9M | 0.5% |
| 63 | ORKAORUKA THERAPEUTICS INC | 55,900 | $4.7M | 0.5% |
| 64 | WAYWAYSTAR HLDG CORP | 169,151 | $4.3M | 0.5% |
| 65 | AGLAGILON HEALTH INC | 52,924 | $4.2M | 0.5% |
| 66 | PODDINSULET CORP | 32,000 | $4.2M | 0.5% |
| 67 | OCULOCULAR THERAPEUTIX INC | 512,000 | $3.9M | 0.4% |
| 68 | BBIOBRIDGEBIO PHARMA INC | 57,100 | $3.8M | 0.4% |
| 69 | SMMTSUMMIT THERAPEUTICS INC | 215,000 | $3.6M | 0.4% |
| 70 | MBXMBX BIOSCIENCES INC | 62,000 | $3.6M | 0.4% |
| 71 | VCELVERICEL CORP | 90,000 | $3.6M | 0.4% |
| 72 | GKOSGLAUKOS CORP | 22,000 | $3.6M | 0.4% |
| 73 | ROIVROIVANT SCIENCES LTD | 82,500 | $3.0M | 0.3% |
| 74 | MDGLMADRIGAL PHARMACEUTICALS INC | 5,655 | $2.8M | 0.3% |
| 75 | ASTHASTRANA HEALTH INC | 79,574 | $2.8M | 0.3% |
| 76 | KRYSKRYSTAL BIOTECH INC | 8,225 | $2.7M | 0.3% |
| 77 | INNVINNOVAGE HLDG CORP | 279,000 | $2.5M | 0.3% |
| 78 | DNLIDENALI THERAPEUTICS INC | 113,585 | $2.3M | 0.3% |
| 79 | ADPTADAPTIVE BIOTECHNOLOGIES COR | 72,500 | $2.1M | 0.2% |
| 80 | RYTMRHYTHM PHARMACEUTICALS INC | 19,000 | $1.8M | 0.2% |
| 81 | STOKSTOKE THERAPEUTICS INC | 61,000 | $1.6M | 0.2% |
| 82 | TNGXTANGO THERAPEUTICS INC | 60,000 | $1.5M | 0.2% |
| 83 | PRVAPRIVIA HEALTH GROUP INC | 66,000 | $1.3M | 0.1% |
| 84 | XENEXENON PHARMACEUTICALS INC | 33,700 | $1.3M | 0.1% |
| 85 | ENSGENSIGN GROUP INC | 3,750 | $645,000 | 0.1% |
| 86 | TXG10X GENOMICS INC | 5,300 | $478,908 | 0.1% |
| 87 | SIONSIONNA THERAPEUTICS INC | 87,500 | $460,250 | 0.1% |
| 88 | CAICARIS LIFE SCIENCES INC | 15,000 | $459,450 | 0.1% |
| 89 | BBNXBETA BIONICS INC | 20,000 | $379,600 | 0% |
| 90 | BRKRBRUKER CORP | 4,500 | $291,375 | 0% |
| 91 | SYKSTRYKER CORPORATION | 1,000 | $275,390 | 0% |
| 92 | AMNAMN HEALTHCARE SVCS INC | 7,200 | $258,264 | 0% |
| 93 | SCISERVICE CORP INTL | 3,200 | $243,680 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-09-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.